Rabeprazole sodium enteric-coated tablets

DRUG4 trials

Sponsors

TenNor Therapeutics (Suzhou) Limited, TenNor Therapeutics Inc., Nanjing First Hospital, Nanjing Medical University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

DepressionFunctional DyspepsiaH.Pylori InfectionHelicobacter Pylori InfectionMyelofibrosis

Phase 1

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

CompletedNCT06337604

TenNor Therapeutics Inc.Helicobacter Pylori Infection

Start: 2017-10-10End: 2017-11-23Updated: 2024-04-01

Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets

Not yet recruitingNCT07608666

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Myelofibrosis

Start: 2026-07-01End: 2026-12-01Target: 17Updated: 2026-07-13

Phase 3

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

CompletedNCT05857163

TenNor Therapeutics (Suzhou) LimitedH.Pylori Infection

Start: 2023-05-18End: 2024-03-26Updated: 2025-08-17

Unknown Phase

Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression

Not yet recruitingNCT06481371

Nanjing First Hospital, Nanjing Medical UniversityDepression, Functional Dyspepsia

Start: 2024-06-30End: 2025-04-30Target: 120Updated: 2024-07-01

Related Papers

Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.

2025-09-102 citations